Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuka Hayakawa

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Plos One|March 24, 2015
High salt intake damages the heart through activation of cardiac (pro) renin receptors even at an early stage of hypertensionYuka Hayakawa, Takuma Aoyama, Chiharu Yokoyama, et al.
Journal of Gastroenterology and Hepatology|May 19, 2022
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver diseaseKento Inada, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 10, 2020
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosisNobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, et al.
Journal of Medical Virology|September 5, 2020
Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis CMayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Journal of Gastroenterology and Hepatology|May 31, 2021
Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patientsShun Kaneko, Masayuki Kurosaki, Kento Inada, et al.
Journal of Viral Hepatitis|January 23, 2021
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatmentSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Plos One|February 23, 2022
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapyKenta Takaura, Masayuki Kurosaki, Kento Inada, et al.
Alimentary Pharmacology & Therapeutics|December 20, 2021
Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortalityMayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|September 29, 2021
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitisKento Inada, Shun Kaneko, Masayuki Kurosaki, et al.
Journal of Gastroenterology and Hepatology|June 21, 2021
Liver fibrosis and fatty liver as independent risk factors for cardiovascular diseaseNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Plos One|March 24, 2015
High salt intake damages the heart through activation of cardiac (pro) renin receptors even at an early stage of hypertensionYuka Hayakawa, Takuma Aoyama, Chiharu Yokoyama, et al.
Journal of Gastroenterology and Hepatology|May 19, 2022
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver diseaseKento Inada, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 10, 2020
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosisNobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, et al.
Journal of Medical Virology|September 5, 2020
Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis CMayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Journal of Gastroenterology and Hepatology|May 31, 2021
Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patientsShun Kaneko, Masayuki Kurosaki, Kento Inada, et al.
Journal of Viral Hepatitis|January 23, 2021
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatmentSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Plos One|February 23, 2022
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapyKenta Takaura, Masayuki Kurosaki, Kento Inada, et al.
Alimentary Pharmacology & Therapeutics|December 20, 2021
Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortalityMayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|September 29, 2021
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitisKento Inada, Shun Kaneko, Masayuki Kurosaki, et al.
Journal of Gastroenterology and Hepatology|June 21, 2021
Liver fibrosis and fatty liver as independent risk factors for cardiovascular diseaseNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
Pageof 5